On 25 October a systematic review in The Surgeon put metabolic surgery and GLP-1 receptor agonists into one table, in the population where both are supposed to protect the kidney: adults with obesity, type 2 diabetes and chronic kidney disease. Surgery came out ahead on nearly every renal endpoint. Five weeks earlier the ASMBS journal had published an analysis of patients already on dialysis in which surgery carried close to three times the one-year mortality of a matched drug cohort.
Neither paper is obviously wrong: they describe patients on opposite sides of a line the field has not drawn — kidney disease not yet at dialysis, where the operation looks protective, and end-stage disease, where the first year looks dangerous.
The review that put both treatments in one table
The authors, from centres in Ireland and the Cleveland Clinic, screened to PRISMA standards and kept six studies — three retrospective cohorts, two Markov models, one randomised trial — describing 2,487 patients, 1,210 operated and 1,277 on a GLP-1 receptor agonist.
Where outcomes were reported in comparable form, the tallies favour surgery: CKD progression 21.7% against 45.1% (p = 0.006), progression to renal failure 24.0% against 43.8% (p = 0.048), microalbuminuria remission 82.4% against 46.9% and CKD remission 82.4% against 55.1% (both p < 0.001), eligibility for transplantation 19.7% against 2.1% (p < 0.001).
Be precise about the document, though. The methods say “basic descriptive statistics were performed using SPSS v26.0” — no pooled estimate, no heterogeneity statistic. The percentages sum raw counts across dissimilar studies, and the denominators are small: 183 and 242 patients for progression, 51 and 49 for remission, 976 and 986 for transplant eligibility. That is a fraction of the 2,487, so the figure atop the abstract describes a literature rather than a cohort — which is why the authors write that surgery “seemingly” reduces risk, and note in their background that, unlike GLP-1 agonists, it is not endorsed for this population.
Five years of matched records
The largest contribution to that lean is a TriNetX analysis in Surgery for Obesity and Related Diseases: 4,481 adults with obesity and established CKD who had a sleeve or bypass between 2010 and 2020, matched against 4,481 who did not, followed five years.
End-stage renal disease occurred in 5.9% of the surgical group against 11.9% (odds ratio 0.47, 95% CI 0.40–0.55), dialysis dependence in 4.1% against 9.0% (0.43, 0.36–0.52), the cardiovascular composite in 15.5% against 27.7% (0.48, 0.42–0.54). Transplant rates were more than double, 4.6% against 2.2% (2.13, 1.67–2.72), and all-cause mortality 5.0% against 16.3% (0.27, 0.23–0.32). Sleeve and bypass performed comparably.
A gap that wide is a signal about who gets operated on as much as about what the operation does. Residual differences in kidney function and unmeasured selection, the authors write, make these associations, not causes.
The other side of dialysis
The US Renal Data System analysis took the population the review mostly excludes — end-stage kidney disease, type 2 diabetes and at least class II obesity, 2010 to 2022 — and emulated three target trials. Against GLP-1 receptor agonists (1,818 patients) surgery was associated with higher one-year mortality (adjusted hazard ratio 2.68, 95% CI 1.98–3.63), easing to 1.34 (1.09–1.64) at three years; against DPP-4 inhibitors (2,111 patients) the one-year ratio was 1.74 (1.35–2.25). Longer-term mortality was comparable, and waitlisting was more frequent after surgery than after either drug class.
Read together, the two SOARD papers suggest a trade: an early hazard around a major operation in people whose kidneys have already failed, bought against better waiting-list access. Both cohorts begin from a BMI threshold our BMI calculator sets out in the terms listing criteria use.
Sleeve or bypass, for someone waiting for a kidney
For patients who hold a transplant or are being listed, a meta-analysis in Obesity Surgery pooled eleven observational studies and 2,553 patients — 1,461 sleeves, 1,092 bypasses — and found the sleeve associated with lower mortality (risk ratio 0.46, 95% CI 0.32–0.66) and lower graft loss (0.39, 0.21–0.73), with similar access to transplantation. The authors also credit it with fewer nutritional complications and steadier drug handling, which matters for narrow-window immunosuppressants. A correction notice appeared on 24 October; the figures above come from the published abstract.
Nothing here settles the procedure question for one person, but it explains why transplant programmes — which answer to graft survival and drug levels, not percentage weight loss — have drifted toward the sleeve while the wider ten-year diabetes-remission record keeps bypass competitive.
Why the guidance lags
The agency most often cited for what surgery improves has not moved. The NIDDK patient page on bariatric-surgery benefits, last reviewed in September 2020, names seven conditions that improve: type 2 diabetes, high blood pressure, heart disease, unhealthy cholesterol, sleep apnea, urinary incontinence, and knee, hip or other body pain. Kidney disease is not among them — the page summarises a literature written before any of these four papers existed.
Closing that gap needs a prospective comparison with pre-specified renal endpoints, stratified by eGFR and dialysis status. The LABS study, funded by NIDDK, is the model for how such a cohort is built, though it was never designed around kidney outcomes.
This archive is independent of NIH and NIDDK — not affiliated with, endorsed by, or speaking for either. It reports published findings and does not offer medical advice.
Sources
- Evaluating the role of metabolic surgery versus GLP1 agonists in patients living with obesity and chronic kidney disease — a systematic review (The Surgeon, published online 25 October 2026)
- Long-term renal, cardiovascular, and survival outcomes in patients with obesity and chronic kidney disease following metabolic and bariatric surgery: a propensity score-matched TriNetX real-world cohort study (Surgery for Obesity and Related Diseases, published online 26 August 2026)
- Metabolic bariatric surgery versus GLP-1 receptor agonists in dialysis patients with diabetes and obesity: a target trial emulation study (Surgery for Obesity and Related Diseases, published online 21 September 2026)
- Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Obese Kidney Transplant Candidates: A Systematic Review, Meta-Analysis, and Development of a Transplant-Specific Decision Framework (Obesity Surgery, August 2026; correction published 24 October 2026)
- NIDDK — Bariatric Surgery: Benefits (patient information page, last reviewed September 2020)